Prostate-specific antigen half-life: A new predictor of progression-free survival and overall survival in Chinese prostate cancer patients

Asian Journal of Andrology

Volumn 11, Issue 4, 2009, Pages 443-450

  Lin, Guo Wen ^a   Yao, Xu Dong ^a   Zhang, Shi Lin ^a   Dai, Bo ^a   Ma, Chun Guang ^a   Zhang, Hai Liang ^a   Shen, Yi Jun ^a   Zhu, Yao ^a   Zhu, Yi Ping ^a   Shi, Guo Hai ^a   Qin, Xiao Jian ^a   Ye, Ding Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FLUTAMIDE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CHINA; DISEASE PROGRESSION; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 69749109858     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.36     Document Type: Article

References (29)

1. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 2008; 102: 786-92.
2. Kang SH, Kim JW, Bae JH, Park HS, Moon DG, et al. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: Quality of life in high-risk prostate cancer patients. Asian J Androl 2006; 8: 629-36.
3. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175: 27-34.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
5. Schulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 2004; 63: 732-6.
6. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, et al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005; 173: 1572-6.
7. Banu E, Banu A, Medioni J, Levy E, Thiounn N, et al. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: Modelization using a standardized set of response criteria. Prostate 2007; 67: 1543-9.
8. Dai B, Ye DW, Kong YY, Shen YJ, Wang BH. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J Androl 2008; 10: 325-31.
9. Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, et al. Prostate-specific antigen change in the European randomized study of screening for prostate cancer, section Rotterdam. Urology 2004; 63: 316-20.
10. Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006; 49: 460-5.
11. Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, et al. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52: 1044-50.
12. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7.
13. Daskivich TJ, Regan MM, Oh WK. Distinct prognostic role of prostate specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology 2007; 70: 527-31.
14. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607-15.
15. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
16. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23: 3343-51.
17. Carducci MA, DeWeese TL, Nelson JB. Prostate-specific antigen and other markers of therapeutic response. Urol Clin North Am 1999; 26: 291-302.
18. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
19. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35.
20. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7.
21. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174: 2191-6.
22. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004; 172: S42-6.
23. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158: 1441-5.
24. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol 1999; 17: 3461-7.
25. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 1996; 88: 1623-34.
26. Chautard D, Cellier P, Dalifard I, Pabot du Chatelard P, Chaussis F, et al. Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: Prognostic value of pretreatment PSA, PSA nadir and PSA half-life. Prog Urol 2002; 12: 421-8.
27. Park YH, Park DS, Jeong CW, Ku JH, Kwak C, et al. PSA half life and PSA doubling time as a predictor of response to androgen deprivation therapy for metastatic prostate cancer. J Urol 2008; 179: S185.
28. Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, et al. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death. Int J Urol 2007; 14: 123-7.
29. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004; 17: 292-306.